Illumina, Inc. is a global leader in genomics, specializing in the development and manufacturing of advanced sequencing and array-based solutions for genetic analysis. Founded in 1998 and headquartered in San Diego, California, Illumina's mission is to improve human health by unlocking the power of the genome. The company serves researchers, clinicians, and pharmaceutical organizations worldwide, enabling breakthroughs in fields such as oncology, reproductive health, infectious diseases, and precision medicine.
With over 7,000 employees, Illumina holds a dominant position in the next-generation sequencing (NGS) market, recognized for its innovative technology platforms like the NovaSeq, NextSeq, and MiSeq systems. Its products and services are widely used in academic research, clinical diagnostics, and biotechnology. In recent years, Illumina has been in the spotlight for its efforts to acquire Grail, a cancer detection company, and for expanding its global footprint through partnerships and new product launches. The company is consistently ranked among the most influential in the life sciences sector, driving advancements that are shaping the future of personalized medicine.